Delayed presentation of late-onset cerebrospinal fluid rhinorrhoea following dopamine agonist therapy for giant prolactinoma.

作者: J K Prague , C L Ward , O G Mustafa , B C Whitelaw , A King

DOI: 10.1530/EDM-14-0020

关键词:

摘要: Summary Therapeutic shrinkage of prolactinomas with dopamine agonists achieves clinical benefit but can expose fistulae that have arisen as a result bony erosion the sella floor and anterior skull base by invasive tumour, resulting in potential development cerebrospinal fluid (CSF) rhinorrhoea, meningitis, rarely pneumocephalus. Onset symptoms is typically within 4 months commencing therapy. The management surgical repair via an endoscopic transnasal transsphenoidal approach. A 23-year-old man presented to Emergency Department acute left limb weakness intermittent headaches. Visual fields were full confrontation. Immediate computed tomography subsequent magnetic resonance imaging (MRI), demonstrated 5 cm lobular/cystic mass invading right cavernous sinus, displacing compressing midbrain, destruction sella. He was referred regional pituitary multidisciplinary team (MDT). Serum prolactin 159 455 mIU/l (7514.37 ng/ml) (normal ranges 100–410 (4.72–19.34 ng/ml)). Cabergoline commenced causing dramatic reduction tumour size resolution neurological symptoms. Further dose titrations required level plateaued significant residual remained. After 13 treatment, he developed continuous daily rhinorrhea, on presenting his general practitioner otolaryngologist. When next seen routine clinic six-months later admitted for urgent repair. Histology confirmed prolactinoma low proliferation index 2% (Ki-67 antibody). In view partial cabergoline resistance completed course conventional radiotherapy. Nine after treatment serum had fallen 621 mIU/l, 12 MRI showed reduced volume. Learning points: † CSF rhinorrhoea occurred initiation cabergoline, suggesting need vigilance throughout Dedicated should be reviewed early patient pathway assess risk agonist There delay before this complication brought attention MDT, associated whilst untreated. This demonstrates patients healthcare professionals educated about recognition facilitate timely appropriate referral MDT specialist advice management. We changed our nurse-led education programme case. An excellent therapeutic response achieved radiotherapy limited surgery having rhinorrhoea.

参考文章(14)
Fei Wang, Hua Gao, Chuzhong Li, Jiwei Bai, Runchun Lu, Lei Cao, Yongtu Wu, Lichuan Hong, Yonggang Wu, Xiaolei Lan, Yazhuo Zhang, Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. Journal of Neuro-oncology. ,vol. 116, pp. 83- 88 ,(2014) , 10.1007/S11060-013-1276-2
M. Brada, B. Rajan, D. Traish, S. Ashley, P. J. Holmes-Sellors, S. Nussey, D. Uttley, The long‐term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas Clinical Endocrinology. ,vol. 38, pp. 571- 578 ,(1993) , 10.1111/J.1365-2265.1993.TB02137.X
S. M. Corsello, G. Ubertini, M. Altomare, R. M. Lovicu, M. G. Migneco, C. A. Rota, C. Colosimo, Giant prolactinomas in men: efficacy of cabergoline treatment Clinical Endocrinology. ,vol. 58, pp. 662- 670 ,(2003) , 10.1046/J.1365-2265.2003.01770.X
Alberto Fernandez, Niki Karavitaki, John A. H. Wass, Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) Clinical Endocrinology. ,vol. 72, pp. 377- 382 ,(2010) , 10.1111/J.1365-2265.2009.03667.X
N S Jones, Advances in the management of CSF leaks. BMJ. ,vol. 322, pp. 122- 123 ,(2001) , 10.1136/BMJ.322.7279.122
Aline B. Moraes, Cintia Marques dos Santos Silva, Leonardo Vieira Neto, Mônica R. Gadelha, Giant prolactinomas: the therapeutic approach Clinical Endocrinology. ,vol. 79, pp. 447- 456 ,(2013) , 10.1111/CEN.12242
Marcello D. Bronstein, Nina Rosa Musolino, Salomon Benabou, Raul Marino, Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas Surgical Neurology. ,vol. 32, pp. 346- 349 ,(1989) , 10.1016/0090-3019(89)90137-7
S. G. I. Suliman, A. Gurlek, J. V. Byrne, N. Sullivan, G. Thanabalasingham, S. Cudlip, O. Ansorge, J. A. H. Wass, Nonsurgical cerebrospinal fluid rhinorrhea in invasive macroprolactinoma: incidence, radiological, and clinicopathological features. The Journal of Clinical Endocrinology and Metabolism. ,vol. 92, pp. 3829- 3835 ,(2007) , 10.1210/JC.2007-0373
Satoko Shimazu, Akira Shimatsu, Shozo Yamada, Naoko Inoshita, Yuko Nagamura, Takeshi Usui, Toshihiko Tsukada, Resistance to dopamine agonists in prolactinoma is correlated with reduction of dopamine D2 receptor long isoform mRNA levels. European Journal of Endocrinology. ,vol. 166, pp. 383- 390 ,(2012) , 10.1530/EJE-11-0656
J. D. N. NABARRO, REVIEW: PITUITARY PROLACTINOMAS Clinical Endocrinology. ,vol. 17, pp. 129- 155 ,(1982) , 10.1111/J.1365-2265.1982.TB01573.X